logo
  Join        Login             Stock Quote

Edwards Lifesciences (EW) Receives Perimount Mitral Heart Valve Approval In China

 November 28, 2012 10:44 AM
 


(By Balaseshan) Edwards Lifesciences Corp. (NYSE: EW) said it has received approval from China's State Food and Drug Administration (SFDA) for its Carpentier-Edwards Perimount Mitral Heart Valve, a replacement heart valve made of bovine pericardial tissue.

Designed for the treatment of mitral valve disease, the Perimount Mitral Heart Valve was introduced into clinical use in 1984 and has demonstrated long-term endurance, as reported in numerous peer-reviewed studies.

The valve is treated with the Carpentier-Edwards ThermaFix process, the only anti-calcification tissue treatment that targets both major calcium binding sites that lead to tissue calcification.

[Related -Stock Upgrades And Downgrades: BBT, EW, FB, MON, MS, MXIM, MU, OXY]

The Carpentier-Edwards Perimount Mitral Heart Valve was approved for U.S. commercial distribution in 2000 and bears the CE mark for countries in the European Union.

"The approval in China of our market-leading PERIMOUNT Mitral Heart Valve represents a clinically significant advancement for patients in the country suffering from mitral heart valve disease," said Donald Bobo Jr., Edwards' corporate vice president, heart valve therapy.

Fuwai Hospital and China National Heart Center's President Shengshou Hu said the Perimount Mitral Heart Valve provides an important therapeutic option for mitral valve replacement, particularly for those patients with lifestyle considerations that may not be compatible with the lifelong blood-thinning medication required with mechanical heart valves.

[Related -Top Insider Purchases: EW, FMER, GE, OPK, NSPR]

Mitral valve disease causes the valve's leaflets to malfunction in one of two primary ways.

When the mitral valve is affected by mitral regurgitation, the leaflets weaken and cannot close properly, so blood leaks backward within the heart; with mitral stenosis, the leaflets stiffen due to the accumulation of calcium and the opening of the valve narrows, restricting normal blood flow.

EW is trading down 0.82% at $83.37 on Wednesday. The stock has been trading between $62.69 and $110.79 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageCrude Rebound

Since the price of crude oil broke below $90 per barrel in September, the Brent global benchmark has been read on...

article imageShould You Invest In The Hottest New Trend In Finance?

Thanks to major changes in regulation, social media and technology, the business of banking has undergone read on...

article imageStrong Attractor in Action Pulling S&P 500 Down

The attractor is formed by the 200-day moving average and the 50% Fibonacci retracement of the up move from read on...

article imageIs The Weak Housing Market A Warning Sign For The US Economy?

Today’s US economic releases – housing starts and business survey data for the manufacturing sector – read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.